Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Eur J Med Chem. 2018 Dec 21;164:179–192. doi: 10.1016/j.ejmech.2018.12.047

Figure 1.

Figure 1.

FDA-approved NAs for treating chronic HBV infection. 1: lamivudine (3TC); 2: telbivudine (LdT); 3: entecavir (ETV); 4: adefovir (ADV); 5: tenofovir disoproxil fumarate (TDF); and 6: tenofovir alafenamide (TAF).